Therapeutic Advances in Respiratory Disease
@tarespirdis.bsky.social
Respiratory Disease | Impact Factor 3.0 | Indexed in: SCIE, MEDLINE, PMC, Scopus, DOAJ, ProQuest | Published by Sage Journals | #OpenAccess
Great to connect with Editor-in-Chief Dr. Nazia Chaudhuri and several Associate Editors of Therapeutic Advances in Respiratory Disease at #ERSCongress2025 yesterday. Valuable discussions around editorial priorities and future plans!
#ERS2025 #RespiratoryDisease
@ild-ipfdoc.bsky.social
#ERS2025 #RespiratoryDisease
@ild-ipfdoc.bsky.social
September 30, 2025 at 8:14 AM
Great to connect with Editor-in-Chief Dr. Nazia Chaudhuri and several Associate Editors of Therapeutic Advances in Respiratory Disease at #ERSCongress2025 yesterday. Valuable discussions around editorial priorities and future plans!
#ERS2025 #RespiratoryDisease
@ild-ipfdoc.bsky.social
#ERS2025 #RespiratoryDisease
@ild-ipfdoc.bsky.social
It's our second day at #ERS2025! Today’s programme includes sessions chaired by our Associate Editors and Editor-in-Chief.
Looking forward to the discussions ahead. #ERSCongress
Looking forward to the discussions ahead. #ERSCongress
September 29, 2025 at 7:17 AM
It's our second day at #ERS2025! Today’s programme includes sessions chaired by our Associate Editors and Editor-in-Chief.
Looking forward to the discussions ahead. #ERSCongress
Looking forward to the discussions ahead. #ERSCongress
📢About to begin: ALERT 2 – Infections, Lung Cancer and Respiratory Symptoms Management
Chaired by our Associate Editor Tom Wilkinson, with editorial board member Francesco Blasi joining as a discussant. Looking forward to catching some of the insights!🫁
#ERSCongress2025
Chaired by our Associate Editor Tom Wilkinson, with editorial board member Francesco Blasi joining as a discussant. Looking forward to catching some of the insights!🫁
#ERSCongress2025
September 28, 2025 at 1:26 PM
📢About to begin: ALERT 2 – Infections, Lung Cancer and Respiratory Symptoms Management
Chaired by our Associate Editor Tom Wilkinson, with editorial board member Francesco Blasi joining as a discussant. Looking forward to catching some of the insights!🫁
#ERSCongress2025
Chaired by our Associate Editor Tom Wilkinson, with editorial board member Francesco Blasi joining as a discussant. Looking forward to catching some of the insights!🫁
#ERSCongress2025
Enjoyed the session on Emerging Clinical Trials in Pulmonary Fibrosis, co-chaired by our Editor-in-Chief Dr. Nazia Chaudhuri.
A popular and timely discussion with lots of interest from attendees.
#ERS2025 #ERSCongress2025 #ClinicalTrials
A popular and timely discussion with lots of interest from attendees.
#ERS2025 #ERSCongress2025 #ClinicalTrials
September 28, 2025 at 10:17 AM
Enjoyed the session on Emerging Clinical Trials in Pulmonary Fibrosis, co-chaired by our Editor-in-Chief Dr. Nazia Chaudhuri.
A popular and timely discussion with lots of interest from attendees.
#ERS2025 #ERSCongress2025 #ClinicalTrials
A popular and timely discussion with lots of interest from attendees.
#ERS2025 #ERSCongress2025 #ClinicalTrials
Great turnout at ALERT 1: Obstructive Airway Diseases in Children and Adults, with our Associate Editor Prof Antonio Spanevello contributing as a discussant.
Engaging presentations and valuable discussion made this a great session🫁 #ERS2025 #RespiratoryMedicine #ERSCongress
Engaging presentations and valuable discussion made this a great session🫁 #ERS2025 #RespiratoryMedicine #ERSCongress
September 28, 2025 at 8:35 AM
Great turnout at ALERT 1: Obstructive Airway Diseases in Children and Adults, with our Associate Editor Prof Antonio Spanevello contributing as a discussant.
Engaging presentations and valuable discussion made this a great session🫁 #ERS2025 #RespiratoryMedicine #ERSCongress
Engaging presentations and valuable discussion made this a great session🫁 #ERS2025 #RespiratoryMedicine #ERSCongress
Immunosuppression is a core part of managing interstitial lung diseases. Learn how outcomes differ between antisynthetase syndrome and systemic sclerosis in response to treatment!
journals.sagepub.com/doi/full/10....
journals.sagepub.com/doi/full/10....
May 9, 2025 at 10:20 AM
Immunosuppression is a core part of managing interstitial lung diseases. Learn how outcomes differ between antisynthetase syndrome and systemic sclerosis in response to treatment!
journals.sagepub.com/doi/full/10....
journals.sagepub.com/doi/full/10....
Don't lose the forest for the trees! Check out this forest plot in our latest meta-analysis on cardiovascular risk in patients with asthma!
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
May 9, 2025 at 10:18 AM
Don't lose the forest for the trees! Check out this forest plot in our latest meta-analysis on cardiovascular risk in patients with asthma!
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
🔥Hot off the press! Glucocorticoids are a cornerstone of therapy for many respiratory conditions. However, there are unintended effects. Here's a comprehensive review of the impact of cumulative glucocorticoid dosage in immunocompromised patients.
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
April 22, 2025 at 9:13 AM
🔥Hot off the press! Glucocorticoids are a cornerstone of therapy for many respiratory conditions. However, there are unintended effects. Here's a comprehensive review of the impact of cumulative glucocorticoid dosage in immunocompromised patients.
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
Severe asthma is a deadly disease ☠️
Read the latest review on inhaled triple therapy in patients with severe asthma!
journals.sagepub.com/doi/10.1177/...
Read the latest review on inhaled triple therapy in patients with severe asthma!
journals.sagepub.com/doi/10.1177/...
April 15, 2025 at 3:32 PM
Severe asthma is a deadly disease ☠️
Read the latest review on inhaled triple therapy in patients with severe asthma!
journals.sagepub.com/doi/10.1177/...
Read the latest review on inhaled triple therapy in patients with severe asthma!
journals.sagepub.com/doi/10.1177/...
April is Sarcoidosis Awareness Month. Throwback to our paper on the management of sarcoidosis.
journals.sagepub.com/doi/full/10....
journals.sagepub.com/doi/full/10....
April 7, 2025 at 4:23 PM
April is Sarcoidosis Awareness Month. Throwback to our paper on the management of sarcoidosis.
journals.sagepub.com/doi/full/10....
journals.sagepub.com/doi/full/10....
From targeted therapy to multidisciplinary management, Cystic Fibrosis has outlined a standard model for research and management of complex respiratory diseases. Please check out our latest review!
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
April 7, 2025 at 4:23 PM
From targeted therapy to multidisciplinary management, Cystic Fibrosis has outlined a standard model for research and management of complex respiratory diseases. Please check out our latest review!
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
📈 Trending this month:
Symptom versus exacerbation control: an evolution in GINA guidelines?
This review explores 25 years of shifting priorities in asthma management—from symptom relief to preventing exacerbations.
🔗 journals.sagepub.com/doi/epdf/10....
Symptom versus exacerbation control: an evolution in GINA guidelines?
This review explores 25 years of shifting priorities in asthma management—from symptom relief to preventing exacerbations.
🔗 journals.sagepub.com/doi/epdf/10....
March 28, 2025 at 5:01 PM
📈 Trending this month:
Symptom versus exacerbation control: an evolution in GINA guidelines?
This review explores 25 years of shifting priorities in asthma management—from symptom relief to preventing exacerbations.
🔗 journals.sagepub.com/doi/epdf/10....
Symptom versus exacerbation control: an evolution in GINA guidelines?
This review explores 25 years of shifting priorities in asthma management—from symptom relief to preventing exacerbations.
🔗 journals.sagepub.com/doi/epdf/10....
🫁 Patients with pulmonary fibrosis & pulmonary hypertension treated with both antifibrotics and pulmonary vasodilators had significantly better transplant-free survival vs antifibrotics alone (HR 0.24, p=0.04), despite worse baseline hemodynamics.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
March 27, 2025 at 3:57 PM
🫁 Patients with pulmonary fibrosis & pulmonary hypertension treated with both antifibrotics and pulmonary vasodilators had significantly better transplant-free survival vs antifibrotics alone (HR 0.24, p=0.04), despite worse baseline hemodynamics.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
🏃 HIIT and MICT were the most effective lower limb aerobic training types for COPD, improving exercise capacity, lung function, breathlessness, and quality of life. HICT showed similar gains but caused more dyspnea.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
March 26, 2025 at 5:31 PM
🏃 HIIT and MICT were the most effective lower limb aerobic training types for COPD, improving exercise capacity, lung function, breathlessness, and quality of life. HICT showed similar gains but caused more dyspnea.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
🫁 Pulmonary rehab significantly improved physical capacity, lung function, QoL, fatigue, dyspnea, and anxiety in long COVID-19 patients across 37 RCTs (n=3,363). Best results with 4–8 week programs combining breathing and multicomponent exercises.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
March 25, 2025 at 6:47 PM
🫁 Pulmonary rehab significantly improved physical capacity, lung function, QoL, fatigue, dyspnea, and anxiety in long COVID-19 patients across 37 RCTs (n=3,363). Best results with 4–8 week programs combining breathing and multicomponent exercises.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
🫁 Multidisciplinary discussion (MDD) significantly altered the diagnosis in 61% of interstitial lung disease (ILD) patients, with notable shifts even in confirmed IPF cases. MDD also influenced prognosis, highlighting its vital role in ILD care.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
March 24, 2025 at 8:08 PM
🫁 Multidisciplinary discussion (MDD) significantly altered the diagnosis in 61% of interstitial lung disease (ILD) patients, with notable shifts even in confirmed IPF cases. MDD also influenced prognosis, highlighting its vital role in ILD care.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
A new CT-based decision tree algorithm predicts recurrence/metastasis risk in stage I SMPLC. Built on 5 key imaging parameters, the model showed AUC > 0.80 across cohorts and subgroups—supporting its role as a practical, noninvasive risk tool.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
March 21, 2025 at 4:59 PM
A new CT-based decision tree algorithm predicts recurrence/metastasis risk in stage I SMPLC. Built on 5 key imaging parameters, the model showed AUC > 0.80 across cohorts and subgroups—supporting its role as a practical, noninvasive risk tool.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
This plain language summary reviews key findings from the GALATHEA & TERRANOVA studies on benralizumab for COPD. Insights from two major trials help identify which patients may benefit most from treatment.
🔗 Read more: journals.sagepub.com/doi/pdf/10.1...
🔗 Read more: journals.sagepub.com/doi/pdf/10.1...
March 20, 2025 at 4:11 PM
This plain language summary reviews key findings from the GALATHEA & TERRANOVA studies on benralizumab for COPD. Insights from two major trials help identify which patients may benefit most from treatment.
🔗 Read more: journals.sagepub.com/doi/pdf/10.1...
🔗 Read more: journals.sagepub.com/doi/pdf/10.1...
A mixed-methods pilot study assessed domiciliary nasal high-flow therapy for people with COPD and severe breathlessness who do not qualify for long-term oxygen therapy. The findings show feasibility, patient adherence, and concerns about long-term use
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
March 19, 2025 at 5:34 PM
A mixed-methods pilot study assessed domiciliary nasal high-flow therapy for people with COPD and severe breathlessness who do not qualify for long-term oxygen therapy. The findings show feasibility, patient adherence, and concerns about long-term use
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
Pulmonary nontuberculous mycobacterial infections (NTM-PD) are rising among women with cystic fibrosis (CF) and non-CF bronchiectasis. This review examines the epidemiology, treatment considerations, and research gaps in NTM-PD among women.
🔗 Read more: journals.sagepub.com/doi/epdf/10....
🔗 Read more: journals.sagepub.com/doi/epdf/10....
March 18, 2025 at 6:05 PM
Pulmonary nontuberculous mycobacterial infections (NTM-PD) are rising among women with cystic fibrosis (CF) and non-CF bronchiectasis. This review examines the epidemiology, treatment considerations, and research gaps in NTM-PD among women.
🔗 Read more: journals.sagepub.com/doi/epdf/10....
🔗 Read more: journals.sagepub.com/doi/epdf/10....